Rose Hill Life Sciences holds an exclusive license to technology from Johns Hopkins related to the improvement of motor function in patients with neurological injuries, in conjunction with the use of psychedelic therapy.

The licensed invention provides methods for treating and improving motor function in subjects with central nervous system injuries by pairing psychedelics with recovery interventions. Further information about the intellectual property can be find here.

The proposed therapeutic approach has the potential to transform how we approach stroke recovery. The licensed interventions are currently being investigated for both safety and efficacy.

Rose Hill is committed to unlocking the therapeutic potential of psilocybin across a range of conditions and to advancing science-driven solutions that could improve the lives of stroke survivors worldwide.